Pfizer registers Phase 3 marstacimab hemophilia trial and elranatamab myeloma comparison studyNov 12Weekly roundup, 10 itemsabrocitinibberobenatide
FDA approves capivasertib combo for PTEN-deficient prostate cancerNov 6Regulatory decisionAstraZenecacapivasertib
Pfizer raises 2026 guidance after Q3, reports pipeline progress and new CFONov 3Quarterly updateBioNTech SEC4 Therapeutics, Inc.
AstraZeneca completes balcinrenone/dapagliflozin PK study; posts two new observational trialsOct 23Weekly roundup, 12 itemsabemaciclibAstraZeneca
Roche adds Phase III trials in flu prophylaxis and diabetes, plus pediatric SMA study updateOct 22Weekly roundup, 6 itemsbaloxavir marboxilChugai PharmaceuticalUpdated
Daiichi Sankyo registers Phase 3b T-DXd sequencing trial; posts RWE and access-program studiesOct 16Weekly roundup, 3 itemsAstraZenecaDaiichi Sankyo
Pfizer registers real-world observational study of marstacimab in hemophilia A and B patientsOct 9Weekly roundup, 8 itemsabrocitinibcyclophosphamide
Pfizer's Ruxience biosimilar supplement approved; breast cancer trials post resultsSep 30Weekly roundup, 8 itemsatirmociclibberobenatideUpdated
Tvardi's TTI-101 breast cancer trial posts results after early terminationSep 24Trial updateTTI-101Tvardi Therapeutics, Incorporated
AstraZeneca's SERENA-4 trial misses main goal for Etcamah in first-line breast cancerSep 14Clinical readoutAstraZenecacamizestrant
FDA approves AstraZeneca's Etcamah for HR-positive breast cancerSep 8Regulatory decisionAstraZenecacamizestrant
FDA drug application records confirm Etcamah approval details, dosage formSep 4Regulatory decisionAstraZenecacamizestrant
Roche results post for two terminated Morpheus umbrella trials; new Phase 1/2 studies registeredAug 7Weekly roundup, 6 itemsatezolizumabBioLineRx, Ltd.
AstraZeneca's Etcamah wins EU approval for 1st-line ER+ breast cancerJul 23Regulatory decisionAstraZenecacamizestrant